Stockscreener 앱 받기
13.38
1.18%
-0.11
전일 마감가:
$13.49
열려 있는:
$13.61
하루 거래량:
119.23K
Relative Volume:
0.07
시가총액:
$1.50B
수익:
$577.74M
순이익/손실:
$-149.78M
주가수익비율:
-9.5571
EPS:
-1.4
순현금흐름:
$-78.21M
1주 성능:
-8.06%
1개월 성능:
+9.72%
6개월 성능:
-19.21%
1년 성능:
-15.36%
1일 변동 폭
$13.27
$13.72
1주일 범위
$13.24
$14.69
52주 변동 폭
$10.87
$34.13
Novocure Ltd Stock (NVCR) Company Profile
명칭
Novocure Ltd
전화
44 (0)15 3475 6700
주소
NO. 4 THE FORUM, ST. HELIER
NVCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
13.40 | 1.51B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
131.42 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
94.78 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
366.14 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.18 | 122.43B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.22 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-12-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-10-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-08-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 개시 | SVB Securities | Outperform |
| 2023-07-31 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2023-06-07 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2023-05-16 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 재확인 | H.C. Wainwright | Buy |
| 2022-11-29 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 개시 | H.C. Wainwright | Buy |
| 2022-02-08 | 개시 | Loop Capital | Buy |
| 2022-02-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2022-01-03 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-07-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-14 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-01-25 | 재확인 | Piper Sandler | Overweight |
| 2020-09-23 | 개시 | Northland Capital | Outperform |
| 2020-09-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | 다운그레이드 | Truist | Buy → Hold |
| 2020-06-01 | 재개 | Oppenheimer | Perform |
| 2020-05-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-04-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2020-03-05 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-29 | 업그레이드 | SunTrust | Hold → Buy |
| 2019-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-07-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2018-11-02 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 개시 | Evercore ISI | Outperform |
| 2018-04-18 | 재확인 | Mizuho | Buy |
| 2018-02-23 | 재확인 | Mizuho | Buy |
| 2017-05-24 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 재확인 | Wedbush | Outperform |
| 2016-01-19 | 개시 | Barclays | Underweight |
| 2015-12-02 | 개시 | Deutsche Bank | Hold |
모두보기
Novocure Ltd 주식(NVCR)의 최신 뉴스
Is NovoCure Limited stock ready for a breakout2025 Breakouts & Breakdowns & High Accuracy Swing Trade Signals - newser.com
NovoCure (NVCR): Evaluating Valuation as METIS Phase 3 Brain Metastases Results Reach Industry Conference Milestone - simplywall.st
Using data tools to time your NovoCure Limited exitJuly 2025 Trends & Target Return Focused Stock Picks - newser.com
NovoCure's (NVCR) Sell (E+) Rating Reiterated at Weiss Ratings - MarketBeat
Final METIS Trial Results for TTFields Therapy Could Be a Game Changer for NovoCure (NVCR) - simplywall.st
Should I buy NovoCure Limited (038) stock before earnings seasonJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com
Why NovoCure Limited (038) stock remains top ratedEarnings Summary Report & Free Weekly Chart Analysis and Trade Guides - newser.com
NovoCure Ltd. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
NovoCure (NASDAQ:NVCR) vs. Evogene (NASDAQ:EVGN) Head-To-Head Analysis - Defense World
NovoCure Limited (NASDAQ:NVCR) Given Average Recommendation of “Hold” by Analysts - Defense World
Published on: 2025-10-05 04:02:03 - newser.com
Analyzing NovoCure Limited with multi timeframe chartsQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com
NovoCure (NVCR): Assessing Valuation After Positive Phase 3 METIS Trial Results Unveiled - simplywall.st
Volume spikes in NovoCure Limited stock – what they mean2025 Support & Resistance & Capital Protection Trading Alerts - newser.com
Will NovoCure Limited (038) stock keep high P E multiplesRecession Risk & Safe Entry Trade Signal Reports - newser.com
Why NovoCure (NVCR) Is Up 9.9% After Phase 3 METIS Trial Success in Brain Metastases - simplywall.st
How NovoCure Limited (038) stock responds to job market shiftsJuly 2025 Outlook & Short-Term High Return Strategies - newser.com
Medical Technology Firm Novocure Schedules Q3 2025 Financial Results with Investor Conference Call - Stock Titan
Novocure to Report Third Quarter 2025 Financial Results - The Globe and Mail
Why NovoCure Limited is moving todayQuarterly Earnings Report & Low Risk High Reward Trade Ideas - newser.com
NovoCure stock rating reiterated at Buy by H.C. Wainwright on METIS trial data - Investing.com Nigeria
NovoCure's (NVCR) "Neutral" Rating Reaffirmed at Wedbush - MarketBeat
Pattern recognition hints at NovoCure Limited upsideTrade Volume Report & Real-Time Chart Breakout Alerts - newser.com
Novocure (NVCR) Announces Positive Phase 3 METIS Trial Results - GuruFocus
Novocure’s cancer therapy delays brain metastases progression By Investing.com - Investing.com Australia
Novocure’s cancer therapy delays brain metastases progression - Investing.com India
15-Month Brain Metastases Control: Novocure's TTFields Therapy Shows Breakthrough in Lung Cancer Trial - Stock Titan
Live market analysis of NovoCure LimitedJuly 2025 Selloffs & Safe Entry Point Identification - newser.com
Why NovoCure Limited stock is rated strong buyJuly 2025 Trends & Precise Swing Trade Entry Alerts - newser.com
Washington Capital Management Inc. Invests $374,000 in NovoCure Limited $NVCR - MarketBeat
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting - Ariva
How NovoCure Limited stock benefits from strong dollarJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com
Regression analysis insights on NovoCure Limited performancePortfolio Risk Report & Fast Gain Swing Alerts - newser.com
Published on: 2025-09-28 23:33:37 - newser.com
NovoCure Limited stock outlook for YEARJuly 2025 Intraday Action & Fast Gain Stock Tips - newser.com
Is NovoCure Limited (038) stock a buy on weaknessJuly 2025 Action & Technical Pattern Based Buy Signals - newser.com
42,600 Shares in NovoCure Limited $NVCR Purchased by Strs Ohio - MarketBeat
How Investors May Respond To NovoCure (NVCR) Securing Japanese Approval for Optune Lua in Lung Cancer - simplywall.st
NovoCure (NVCR): Assessing Valuation After Japan Approves Optune Lua for Advanced Lung Cancer Therapy - simplywall.st
Using Ichimoku Cloud for NovoCure Limited technicalsTrade Risk Assessment & Fast Moving Stock Trade Plans - newser.com
NovoCure Limited $NVCR Shares Acquired by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC - MarketBeat
Multi factor analysis applied to NovoCure LimitedDip Buying & Stepwise Trade Signal Implementation - newser.com
Rally Mode: What is the long term forecast for NovoCure Limited stock2025 Price Targets & Low Drawdown Momentum Ideas - خودرو بانک
Novocure Ltd (NVCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Novocure Ltd 주식 (NVCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Brackmann Christoph | Chief Financial Officer |
Jul 29 '25 |
Buy |
11.59 |
20,000 |
231,800 |
141,150 |
| Stafford Kristin | Director |
Jun 03 '25 |
Sale |
17.28 |
999 |
17,259 |
3,054 |
| LEUNG GABRIEL | Director |
Jun 03 '25 |
Sale |
17.31 |
999 |
17,297 |
81,229 |
| Madden Martin J. | Director |
Jun 03 '25 |
Sale |
17.19 |
999 |
17,176 |
18,674 |
| Scannell Timothy J | Director |
Jun 03 '25 |
Sale |
17.32 |
999 |
17,299 |
6,018 |
| HILLEMAN JERYL L | Director |
Jun 03 '25 |
Sale |
17.26 |
999 |
17,247 |
5,591 |
| Ocean Allyson J | Director |
Jun 03 '25 |
Sale |
17.29 |
999 |
17,269 |
3,054 |
| VERNON W ANTHONY | Director |
Jun 03 '25 |
Sale |
17.35 |
999 |
17,329 |
167,887 |
| Hung David | Director |
Jun 03 '25 |
Sale |
17.30 |
999 |
17,280 |
12,195 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Jun 02 '25 |
Sale |
17.50 |
30,196 |
528,413 |
168,452 |
0.14%
0.38%
자본화:
|
볼륨(24시간):